TriangleDaratumumab and Recombinant Human… (NCT07485647)
Daratumumab and Recombinant Human Hyaluronidase trial for Multiple Myeloma (NCT07485647). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults aged 18–70 with newly-diagnosed multiple myeloma responding at least partially after autologous stem-cell transplantation. Induction must include a proteasome inhibitor, an immunomodulatory drug, and anti-CD38 treatment.
The idea: daratumumab targets CD38 on myeloma cells. Maintenance injections under the skin are spaced every eight weeks in year one, then every sixteen weeks in years two through four, alongside daily oral lenalidomide. Researchers measure residual disease and compare results with historical patients.
This phase 2 study plans 50 patients. Eden Biltibo leads at Vanderbilt in Nashville, one recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.